The Pharma Data

FEBRUARY 23, 2022

* Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus). * efficacy against any symptomatic COVID-19 disease, in line with expected vaccine effectiveness in today’s environment dominated by variants of concern.

Vaccine 52

Vaccine Virus Trials Immune Response 52

The Pharma Data

MARCH 23, 2022

“When the COVID-19 pandemic started, our multidisciplinary research teams switched our investigations of other viruses and bacteria to focus on a potential treatment for what was then a challenging new virus for us,” says Children’s Center microbiologist Lori Jones-Brando, Ph.D., alone each year.

Virus 52

Virus Immune Response Research Treatment 52

The Pharma Data

JANUARY 4, 2021

officials ramped up efforts to vaccinate more Americans, scientists around the world wrestled with whether it would make sense to delay the second doses everyone will need so more people can be vaccinated more quickly. Each vaccine would still be delivered in two doses given four weeks apart. MONDAY, Jan. 4, 2021 — As U.S.

Vaccine 52

Vaccine Immune Response Virus Hospitals 52

The Pharma Data

MARCH 25, 2021

European Medicines Agency to Conduct First-Ever Parallel Assessment of a Medicinal Product, Takeda’s Dengue Vaccine Candidate (TAK-003), for use in the EU; Countries Outside of the EU through the EU-M4all (Previously Article 58) Procedure. About TAK-003. 4,5 Efficacy varied by serotype.

Vaccine 52

Vaccine Virus Trials Hospitals 52

The Pharma Data

OCTOBER 18, 2021

Northwestern Medicine scientists have shown for the first time that coronavirus vaccines and prior coronavirus infections can provide broad immunity against other, similar coronaviruses. The findings build a rationale for universal coronavirus vaccines that could prove useful in the face of future epidemics.

Vaccine 40

Vaccine Immune Response Virus Hospitals 40

The Pharma Data

DECEMBER 16, 2020

Food and Drug Administration (FDA) advisory panel in regard to the COVID-19 vaccine from Moderna. The Vaccines and Related Biological Products Advisory Committee will be determining whether the product should be authorized for emergency use, according to CNBC. The vote itself is not slated to take place until after 3 p.m.

Vaccine 52

Vaccine Immune Response FDA FDA Approval 52

NIH Director's Blog: Drug Development

JUNE 30, 2020

A major one is: just how well do those particular antibodies neutralize the virus to fight off the infection and help someone recover from COVID-19? Fortunately, most people get better—but should the typical antibody response take the credit? Not surprisingly, all volunteers had produced antibodies in response to the virus.

Immune Response 52

Immune Response Virus Vaccine Research 52

The Pharma Data

JANUARY 5, 2021

Food and Drug Administration said Monday that any American who gets the Moderna or Pfizer coronavirus vaccines must get two full doses, despite international debate on possible ways to stretch vaccine supply. vaccine effort just as the public is starting to trust the program, Dr. Anthony Fauci told The New York Times.

Vaccine 52

Vaccine FDA Virus Immune Response 52

The Pharma Data

MARCH 8, 2022

SARS-CoV-2 viruses can hide from recognition by the immune system. However, the antiviral immune receptor RIG-I can be stimulated, which improves protection against lethal SARS-CoV-2 infections. The ongoing SARS-CoV-2 pandemic has caused an imminent urge for both antiviral therapeutical drugs and vaccines.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

The Pharma Data

JANUARY 15, 2021

15, 2021 (American Heart Association News) — Experts have a simple answer for heart and stroke patients questioning whether they need a COVID-19 vaccination. The Food and Drug Administration-approved vaccines pose no special problems for such patients, said Elkind, who also is president of the American Heart Association.

Vaccine 52

Vaccine Virus Immune Response Disease 52

The Pharma Data

NOVEMBER 23, 2021

The population’s immunity to SARS-CoV-2, achieved either through infection or vaccination, is crucial to overcome the COVID-19 pandemic. In addition, people with high levels of antibodies against harmless coronaviruses were less likely to have been hospitalized after catching SARS-CoV-2.

Immune Response 52

Immune Response Vaccine Virus Hospitals 52

The Pharma Data

SEPTEMBER 14, 2020

A new antibody treatment is to be trialled on Covid-19 patients in UK hospitals. Prof Martin Landray from the University of Oxford, who is co-leading the Recovery Trial, said: “This is the first type of treatment that’s targeted for this specific virus. This is then given to patients, immediately boosting their immune response.

Trials 52

Trials Immune Response Virus Vaccine 52

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. This is the focus of vaccines in development and convalescent plasma therapy. The test targets antibodies against the spike protein. said Thomas Schinecker, CEO Roche Diagnostics.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

The Pharma Data

NOVEMBER 17, 2020

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. The research at the University Hospital in Bern receives a boost through this funding and recognizes the work of our research teams.

Vaccine 40

Vaccine Hospitals Immune Response Compliance 40

The Pharma Data

DECEMBER 18, 2020

Food and Drug Administration issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the U.S. Hahn , M.D.

Vaccine 52

Vaccine FDA Clinical Trials FDA Approval 52

The Pharma Data

SEPTEMBER 6, 2021

Based on current evidence, there is no urgent need for the administration of booster doses of vaccines to fully vaccinated individuals in the general population, according to a technical report issued by the European Centre for Disease Prevention and Control (ECDC).

Long-Term Care Facilities 52

Long-Term Care Facilities Vaccine Immune Response Virus 52

The Pharma Data

JANUARY 11, 2021

The study from China involved more than 1,700 patients first diagnosed with the virus in Wuhan between January and May, and then followed to June and September. Bin Cao, from the National Center for Respiratory Medicine at the China-Japan Friendship Hospital and Capital Medical University, both in Beijing. MONDAY, Jan.

Hospitals 52

Hospitals Virus Vaccine Immune Response 52

Drug Discovery World

APRIL 20, 2023

To date, it seems that the likely mechanism of post- Covid-19 cognitive impairment is neuroinflammation triggered by the peripheral / systemic inflammation caused by the virus. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis,” Brain, Behavior, and Immunity, vol. F Ceban et al.,

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

The Pharma Data

JANUARY 24, 2021

(NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110.

Vaccine 52

Vaccine Immune Response Virus Production 52

The Pharma Data

JANUARY 11, 2021

Testing Therapies, Antivirals and Vaccines. By the end of January, Johnson & Johnson is expected to deliver preliminary trial results for its one-dose COVID-19 vaccine candidate. . One of the open questions about the various vaccines against COVID-19 has been how long the protection offered will last. Other Industry News.

Vaccine 52

Vaccine Clinical Trials Immune Response Virus 52

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

hospitals are stretched to the limit trying to help people battling serious cases of COVID-19. A leader in this critical effort is NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV ) initiative, a public-private partnership involving 20 biopharmaceutical companies, academic experts, and multiple federal agencies.

Clinical Trials 52

Clinical Trials Hospitals Vaccine Trials 52

The Pharma Data

MARCH 29, 2022

Spinner, MD, Consulting Physician Infectious Diseases and Pandemic Officer at the University Hospital Rechts der Isar and adjunct teaching professor at the Technical University of Munich, Munich, Germany, said: “Increasing COVID-19 cases, driven by the highly-transmissible BA.2 1-3 Evusheld was generally well-tolerated in the trial.

Vaccine 52

Vaccine Virus Immune Response Government 52

NIH Director's Blog: Drug Development

FEBRUARY 1, 2022

The ACE2 drug candidate, which is soluble and degrades in the body, also proved ineffective in neutralizing the virus. In the lab, it also appeared to neutralize the virus as well as monoclonal antibodies used to treat COVID-19. In fact, the decoy bound just as well, if not better, to new variants compared to the original virus.

Virus 52

Virus Clinical Trials Engineering Immune Response 52

The Pharma Data

NOVEMBER 29, 2020

Early interim data show Cytomegalovirus (CMV)-negative kidney transplant recipients vaccinated with three doses of HB-101 had reduced incidence of CMV viremia, reduced antiviral use and no CMV disease. Observed CMV-neutralizing antibody responses and tolerability profile are consistent with previous interim results.

Vaccine 52

Vaccine Clinical Trials Disease Trials 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

Vaccine 52

Vaccine Trials FDA Clinical Trials 52

Agency IQ

DECEMBER 1, 2023

It also stated that companies should consider whether an investigational product might interact with an administered vaccine for Covid-19. For instance, if the product is intended to prevent hospitalization, patients at a high risk of progression to severe disease should be enrolled in the trial.

FDA 40

FDA Clinical Trials Vaccine Trials 40

Broad Institute

DECEMBER 6, 2023

The immune system can carry out many biological processes, from killing viruses to fighting cancer, thanks in large part to approximately 100 key cell-signaling proteins called cytokines, which instruct immune cells what to do. For many immune-mediated diseases, there's no cure or treatment. What makes this study significant?

Immune Response 138

Immune Response RNA Medical Schools Disease 138

The Pharma Data

JANUARY 3, 2021

The clinical study was completed in collaboration with scientific teams at the Harvard Medical School (Boston, USA), Santa Casa de Misericórdia de Santos Hospital (Santos, Brazil) and INTRIALS, a world-class, full-service Latin American CRO based in São Paulo, Brazil. . NEW YORK and LONDON, Jan. In a humanized mouse model (NOD/SCID IL2?c-/-),

Clinical Trials 40

Clinical Trials Science Treatment Trials 40

The Pharma Data

MARCH 3, 2022

The FDA decision is informed by the results of the Phase 2b proof-of-concept study of RSVpreF (NCT04032093), a global, double-blinded, placebo-controlled study that assessed the safety and immunogenicity of RSVpreF in healthy pregnant women ages 18 through 49 years old, who were vaccinated between 28- and 36-weeks gestation, and their infants.

Virus 52

Virus Vaccine Clinical Trials FDA 52

Codon

AUGUST 27, 2024

Consider Alice, a 49-year-old woman (and hypothetical patient) who walked into a hospital in Puerto Rico with joint pain, a headache, nausea, and a low fever. While Alice was lucky that her infections were identified at the hospital, it would have been even better had they been identified before she arrived.

DNA 84

DNA Hospitals Laboratories Virus 84

The Pharma Data

JUNE 26, 2021

Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. JUNE 22 , 2021.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

NOVEMBER 24, 2020

24, 2020 – At least thee new COVID-19 vaccine candidates are already in the pipeline, will a roll-out expected early in the new year. “These are immune responses, so if you feel something after vaccination, you should expect to feel that. ” Another vaccine candidate. . TUESDAY, Nov. Meanwhile, U.S.

Vaccine 52

Vaccine Virus Immune Response Hospitals 52

The Pharma Data

JANUARY 29, 2021

29, 2021 — The new coronavirus is mutating in an attempt to elude vaccines and treatments, putting a greater onus on Americans to get vaccinated and use social distancing measures to avoid infection, U.S. FRIDAY, Jan. health officials said Friday. New COVID-19 variants out of South Africa and Brazil — B.1.351

Vaccine 52

Vaccine Immune Response Virus Disease 52

The Pharma Data

NOVEMBER 23, 2020

As the Pfizer-BioNTech COVID-19 vaccine is being evaluated by the U.S. Food and Drug Administration (FDA) and the Moderna vaccine is soon to follow, here’s a look at several of the top COVID-19 vaccine candidates and where they stand as of today. The prices for the vaccines are moving targets, dependent upon the amount ordered.

Vaccine 52

Vaccine Virus Immune Response FDA 52

Drug Discovery World

AUGUST 1, 2023

As such, the company has entered into a sponsored research agreement with the Children’s Hospital of Philadelphia (CHOP) in the US to develop a TUBB4A-related leukodystrophy treatment from ASOs. This Phase I trial will test the experimental vaccine, known as H1ssF-3928 mRNA-LNP, for safety and its ability to induce an immune response.

RNA 130

RNA Vaccine Drugs Disease 130

The Pharma Data

SEPTEMBER 2, 2021

First subjects vaccinated in study of Pfizer’s RSV bivalent prefusion F subunit investigational vaccine candidate in adults ages 60 or older. RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available. NEW YORK–(BUSINESS WIRE)– Pfizer Inc. Jansen, Ph.D.,

Clinical Trials 52

Clinical Trials Trials Vaccine Virus 52

Codon

SEPTEMBER 29, 2024

On the surface, they hadn't deviated much from the early 2020s: a virus infected a cell and released the genetic therapy hidden within. Dozens of diverse chemical markers and de novo , evolutionary distinct proteins littered the virus' surface, indicating a previously unseen biological logic.

Engineering 125

Engineering Virus DNA Therapies 125